by tmourit | Mar 6, 2026 | Audits, Quality
On January 16, 2026, the U.S. Food and Drug Administration issued a Warning Letter to Boothwyn Pharmacy, LLC following a 2025 inspection of its sterile compounding operations. For organizations involved in sterile drug production — particularly compounding pharmacies,... by tmourit | Feb 27, 2026 | Audits, Quality
Corrective and Preventive Action (CAPA) is one of the most frequently cited areas in FDA inspections, ISO audits, and notified body reviews. Despite this, many organizations still struggle to implement CAPA systems that are both effective in practice and defensible to... by tmourit | Feb 20, 2026 | Audits, Quality
For many early stage life science companies, regulatory compliance feels like a catch-22. Regulators expect robust quality systems, documented processes, and ongoing oversight—yet hiring a full in-house Quality Assurance (QA) team is often unrealistic due to cost,... by tmourit | Feb 13, 2026 | Audits, Quality
As global supply chains grow more complex and regulatory expectations continue to tighten, supplier quality management is undergoing a fundamental shift. Traditional, checklist-driven supplier qualification models are no longer sufficient. In their place,... by tmourit | Feb 6, 2026 | Audits, Quality, Regulatory
Artificial intelligence is rapidly entering quality and regulatory functions across the life sciences industry. From document analysis and gap assessments to trend detection and compliance monitoring, AI offers meaningful efficiency gains. However, in regulated... by tmourit | Jan 30, 2026 | Audits, Quality, Regulatory
The short answer: AI does not replace QA or RA expertise. It reshapes it. When implemented correctly, AI reduces administrative burden, increases visibility, and elevates QA and RA professionals into more strategic, decision driven roles. The Traditional QA and RA...